SEC Comment Letter for AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Nov 30, 2017
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Nov. 30, 2017 · CIK: 0001385818 · Accession: 0000000000-17-042024
AI Filing Summary & Sentiment
Reasoning
Letter
November 30, 2017 Joshua R. Disbrow Chief Executive Officer Aytu Bioscience, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Aytu Bioscience, Inc. Registration Statement on Form S-3 Filed November 22, 2017 File No. 333-221735Re: Dear Mr. Disbrow: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Marcelle S. Balcombe, Esq.
Show Raw Text
November 30, 2017
Joshua R. Disbrow
Chief Executive Officer
Aytu Bioscience, Inc.
373 Inverness Parkway, Suite 206
Englewood, Colorado 80112
Aytu Bioscience, Inc.
Registration Statement on Form S-3
Filed November 22, 2017
File No. 333-221735Re:
Dear Mr. Disbrow:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Marcelle S. Balcombe, Esq.